View Future GrowthVitalist 과거 순이익 실적과거 기준 점검 0/6Vitalist은 연평균 25.8%의 비율로 수입이 증가해 온 반면, Consumer Durables 산업은 연평균 1.9%의 비율로 감소했습니다. 매출은 연평균 17.8%의 비율로 감소했습니다.핵심 정보25.82%순이익 성장률42.97%주당순이익(EPS) 성장률Consumer Durables 산업 성장률24.52%매출 성장률-17.77%자기자본이익률n/a순이익률-83.82%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jul 20Vitalist Inc., Annual General Meeting, Sep 29, 2026Vitalist Inc., Annual General Meeting, Sep 29, 2026. Location: at 2100 livingston place, 222 3 ave sw, ab t2p 0b4, calgary Canada공고 • Jul 02Vitalist Inc. Announces Resignation of Nick Padula from Chief Revenue Officer RoleVitalist Inc. announced that Chief Revenue Officer Nick Padula would be concluding his role with the Company following his support of the post-acquisition integration and commercial transition of Somatix Inc. Nick and the Vitalist team were working closely together to ensure a seamless hand-off of responsibilities over the coming weeks. In connection with Mr. Padula's departure, Vitalist's commercial and sales operations would report directly to CEO Kalvie Legat with health and wellness business development continuing to report through Dr. Charles Herman who serves as CSO of Vitalist and CEO of Vitalist subsidiary Somatix Inc.공고 • May 01Vitalist Inc. (TSXV:VITA) acquired Somatix, Inc. for CAD 6.7 million.Vitalist Inc. (TSXV:VITA) entered into a definitive merger agreement to acquire Somatix, Inc. for CAD 6.7 million on March 30, 2026. The consideration consists of 15.58 million common equity of Vitalist Inc. to be issued for common equity of Somatix, Inc. Following the Closing, Somatix, Inc's Stockholders will hold approximately 23.4% of Vitalist's issued and outstanding common shares. Upon closing of the Transaction, Charles Herman will be appointed as Chief Science Officer of Vitalist and will continue to serve as CEO of Somatix and Nick Padula joins the executive team as President of Somatix and Chief Revenue Officer of both Somatix and Vitalist. For the period ending December 31, 2025, Somatix, Inc. reported total revenue of CAD 0.15 million ($0.11 million) and net loss of CAD 4.25 million ($3.05 million). As of December 31, 2025, Somatix, Inc. reported total assets of CAD 3.24 million ($2.33 million). Completion remains subject to the final approval of TSX Venture Exchange and the satisfaction of customary closing conditions. Kingswood Capital Partners, LLC acted as financial advisor for Somatix, Inc. Kier Advisory Services acted as financial advisor for Vitalist Inc. Kingswood Capital Partners, LLC will receive a finder’s fee consisting of CAD 0.14 million ($0.1 million) in cash and Vitalist common shares equivalent to a value of CAD 0.06 million ($0.05 million), conditional upon the Closing. Vitalist Inc. (TSXV:VITA) completed the acquisition of Somatix, Inc. on April 30, 2026. Under the terms of the transaction, Vitalist issued 15,581,854 of its common shares in exchange for 100% of the common stock of Somatix. Following closing, the former Somatix stockholders held approximately 23.24% of the issued and outstanding common shares of Vitalist. Kingswood Capital Partners, LLC was paid a financial advisory fee consisting of CAD 0.13 million ($0.1 million) in cash and 87,812 common shares of Vitalist issued at a price of CAD 0.71 per share.공고 • Apr 02Vitalist Inc. Announces Executive AppointmentsVitalist Inc. announced that Dr. Charles Herman will be appointed as Chief Science Officer of Vitalist and will continue to serve as CEO of Somatix. Dr. Herman is a distinguished surgeon and healthcare executive with over 20 years of experience in clinical practice and medical technology innovation. In addition to his leadership at Somatix, Dr. Herman serves as a Portfolio Manager at Forefront Analytics, where he applies quantitative insights to healthcare investments. He previously served as Chief Medical Executive for multiple healthcare systems and has held executive leadership and faculty positions at major medical institutions and universities. Dr. Herman holds an M.D. from Albany Medical College in New York and an M.B.A. from the Wharton School of the University of Pennsylvania, where he is a Palmer Scholar. Nick Padula joins the executive team as Chief Revenue Officer of Vitalist. Mr. Padula is a senior executive with over 30 years of experience driving market share growth and operational excellence across major healthcare and medical technology firms. He has previously held senior leadership roles at Philips Healthcare, GE Healthcare, and Health Recovery Solutions, where he led large-scale commercial organizations and successfully integrated complex global acquisitions.공고 • Apr 01Vitalist Inc. (TSXV:VITA) entered into a definitive merger agreement to acquire Somatix, Inc. for CAD 6.7 million.Vitalist Inc. (TSXV:VITA) entered into a definitive merger agreement to acquire Somatix, Inc. for CAD 6.7 million on March 30, 2026. The consideration consists of 15.58 million common equity of Vitalist Inc. to be issued for common equity of Somatix, Inc. Following the Closing, Somatix, Inc's Stockholders will hold approximately 23.4% of Vitalist's issued and outstanding common shares. Upon closing of the Transaction, Charles Herman will be appointed as Chief Science Officer of Vitalist and will continue to serve as CEO of Somatix and Nick Padula joins the executive team as President of Somatix and Chief Revenue Officer of both Somatix and Vitalist. For the period ending December 31, 2025, Somatix, Inc. reported total revenue of CAD 0.15 million ($0.11 million) and net loss of CAD 4.25 million ($3.05 million). As of December 31, 2025, Somatix, Inc. reported total assets of CAD 3.24 million ($2.33 million). Completion remains subject to the final approval of TSX Venture Exchange and the satisfaction of customary closing conditions. Kingswood Capital Partners, LLC acted as financial advisor for Somatix, Inc. Kier Advisory Services acted as financial advisor for Vitalist Inc. Kingswood Capital Partners, LLC will receive a finder’s fee consisting of CAD 0.14 million ($0.1 million) in cash and Vitalist common shares equivalent to a value of CAD 0.06 million ($0.05 million), conditional upon the Closing.공고 • Dec 02Vitalist Inc. and MicroEJ Announce New Reebok Smartwatch Powered by VitalOSVitalist Inc. and MicroEJ announced the launch of the first Reebok smartwatch powered by VitalOS, marking the public debut of an operating system designed to support consumer brands entering the wearable market. With Reebok as the first commercial implementation, VitalOS illustrates the platform's capabilities and showcases its capabilities, providing an alternative approach to developing wearables without reliance on proprietary ecosystems. VitalOS is built on MicroEJ's proven virtualization technology, MicroEJ VEE, and its wearable solution, VEE Wear -- part of a platform that already powers more than 400 million connected devices worldwide. Together, the companies have created a foundation that streamlines the cost, speed, and scale of wearable development: Low-power architecture designed to support extended battery performance; 6-9 month development cycles; Customization options for brand-specific experiences; Hardware-agnostic scalability.매출 및 비용 세부 내역Vitalist가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:VTLS.F 매출, 비용 및 순이익 (CAD Millions)날짜매출순이익일반관리비연구개발비31 Dec 255-44030 Sep 256-34030 Jun 255-44031 Mar 255-43031 Dec 245-34030 Sep 244-44030 Jun 242-54031 Mar 24244031 Dec 233-125030 Sep 234-176030 Jun 236-177031 Mar 238-288131 Dec 2210-148130 Sep 229-108130 Jun 229-108131 Mar 227-108031 Dec 215-107030 Sep 217-127030 Jun 218-148031 Mar 219-148031 Dec 2010-1510030 Sep 209-1410130 Jun 208-119031 Mar 207-109031 Mar 193-34031 Mar 181-11031 Mar 172010양질의 수익: VTLS.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: VTLS.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: VTLS.F는 수익성이 없지만 지난 5년 동안 연평균 25.8%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 VTLS.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: VTLS.F은 수익성이 없어 지난 해 수익 성장률을 Consumer Durables 업계(-15.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: VTLS.F의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YConsumer-durables 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/23 10:21종가2026/07/23 00:00수익2025/12/31연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Vitalist Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공고 • Jul 20Vitalist Inc., Annual General Meeting, Sep 29, 2026Vitalist Inc., Annual General Meeting, Sep 29, 2026. Location: at 2100 livingston place, 222 3 ave sw, ab t2p 0b4, calgary Canada
공고 • Jul 02Vitalist Inc. Announces Resignation of Nick Padula from Chief Revenue Officer RoleVitalist Inc. announced that Chief Revenue Officer Nick Padula would be concluding his role with the Company following his support of the post-acquisition integration and commercial transition of Somatix Inc. Nick and the Vitalist team were working closely together to ensure a seamless hand-off of responsibilities over the coming weeks. In connection with Mr. Padula's departure, Vitalist's commercial and sales operations would report directly to CEO Kalvie Legat with health and wellness business development continuing to report through Dr. Charles Herman who serves as CSO of Vitalist and CEO of Vitalist subsidiary Somatix Inc.
공고 • May 01Vitalist Inc. (TSXV:VITA) acquired Somatix, Inc. for CAD 6.7 million.Vitalist Inc. (TSXV:VITA) entered into a definitive merger agreement to acquire Somatix, Inc. for CAD 6.7 million on March 30, 2026. The consideration consists of 15.58 million common equity of Vitalist Inc. to be issued for common equity of Somatix, Inc. Following the Closing, Somatix, Inc's Stockholders will hold approximately 23.4% of Vitalist's issued and outstanding common shares. Upon closing of the Transaction, Charles Herman will be appointed as Chief Science Officer of Vitalist and will continue to serve as CEO of Somatix and Nick Padula joins the executive team as President of Somatix and Chief Revenue Officer of both Somatix and Vitalist. For the period ending December 31, 2025, Somatix, Inc. reported total revenue of CAD 0.15 million ($0.11 million) and net loss of CAD 4.25 million ($3.05 million). As of December 31, 2025, Somatix, Inc. reported total assets of CAD 3.24 million ($2.33 million). Completion remains subject to the final approval of TSX Venture Exchange and the satisfaction of customary closing conditions. Kingswood Capital Partners, LLC acted as financial advisor for Somatix, Inc. Kier Advisory Services acted as financial advisor for Vitalist Inc. Kingswood Capital Partners, LLC will receive a finder’s fee consisting of CAD 0.14 million ($0.1 million) in cash and Vitalist common shares equivalent to a value of CAD 0.06 million ($0.05 million), conditional upon the Closing. Vitalist Inc. (TSXV:VITA) completed the acquisition of Somatix, Inc. on April 30, 2026. Under the terms of the transaction, Vitalist issued 15,581,854 of its common shares in exchange for 100% of the common stock of Somatix. Following closing, the former Somatix stockholders held approximately 23.24% of the issued and outstanding common shares of Vitalist. Kingswood Capital Partners, LLC was paid a financial advisory fee consisting of CAD 0.13 million ($0.1 million) in cash and 87,812 common shares of Vitalist issued at a price of CAD 0.71 per share.
공고 • Apr 02Vitalist Inc. Announces Executive AppointmentsVitalist Inc. announced that Dr. Charles Herman will be appointed as Chief Science Officer of Vitalist and will continue to serve as CEO of Somatix. Dr. Herman is a distinguished surgeon and healthcare executive with over 20 years of experience in clinical practice and medical technology innovation. In addition to his leadership at Somatix, Dr. Herman serves as a Portfolio Manager at Forefront Analytics, where he applies quantitative insights to healthcare investments. He previously served as Chief Medical Executive for multiple healthcare systems and has held executive leadership and faculty positions at major medical institutions and universities. Dr. Herman holds an M.D. from Albany Medical College in New York and an M.B.A. from the Wharton School of the University of Pennsylvania, where he is a Palmer Scholar. Nick Padula joins the executive team as Chief Revenue Officer of Vitalist. Mr. Padula is a senior executive with over 30 years of experience driving market share growth and operational excellence across major healthcare and medical technology firms. He has previously held senior leadership roles at Philips Healthcare, GE Healthcare, and Health Recovery Solutions, where he led large-scale commercial organizations and successfully integrated complex global acquisitions.
공고 • Apr 01Vitalist Inc. (TSXV:VITA) entered into a definitive merger agreement to acquire Somatix, Inc. for CAD 6.7 million.Vitalist Inc. (TSXV:VITA) entered into a definitive merger agreement to acquire Somatix, Inc. for CAD 6.7 million on March 30, 2026. The consideration consists of 15.58 million common equity of Vitalist Inc. to be issued for common equity of Somatix, Inc. Following the Closing, Somatix, Inc's Stockholders will hold approximately 23.4% of Vitalist's issued and outstanding common shares. Upon closing of the Transaction, Charles Herman will be appointed as Chief Science Officer of Vitalist and will continue to serve as CEO of Somatix and Nick Padula joins the executive team as President of Somatix and Chief Revenue Officer of both Somatix and Vitalist. For the period ending December 31, 2025, Somatix, Inc. reported total revenue of CAD 0.15 million ($0.11 million) and net loss of CAD 4.25 million ($3.05 million). As of December 31, 2025, Somatix, Inc. reported total assets of CAD 3.24 million ($2.33 million). Completion remains subject to the final approval of TSX Venture Exchange and the satisfaction of customary closing conditions. Kingswood Capital Partners, LLC acted as financial advisor for Somatix, Inc. Kier Advisory Services acted as financial advisor for Vitalist Inc. Kingswood Capital Partners, LLC will receive a finder’s fee consisting of CAD 0.14 million ($0.1 million) in cash and Vitalist common shares equivalent to a value of CAD 0.06 million ($0.05 million), conditional upon the Closing.
공고 • Dec 02Vitalist Inc. and MicroEJ Announce New Reebok Smartwatch Powered by VitalOSVitalist Inc. and MicroEJ announced the launch of the first Reebok smartwatch powered by VitalOS, marking the public debut of an operating system designed to support consumer brands entering the wearable market. With Reebok as the first commercial implementation, VitalOS illustrates the platform's capabilities and showcases its capabilities, providing an alternative approach to developing wearables without reliance on proprietary ecosystems. VitalOS is built on MicroEJ's proven virtualization technology, MicroEJ VEE, and its wearable solution, VEE Wear -- part of a platform that already powers more than 400 million connected devices worldwide. Together, the companies have created a foundation that streamlines the cost, speed, and scale of wearable development: Low-power architecture designed to support extended battery performance; 6-9 month development cycles; Customization options for brand-specific experiences; Hardware-agnostic scalability.